Henry KaminskiChair, Department of Neurology
Meta Amalia Neumann Professorship in Neurology
Professor of Neurology
Professor of Pharmacology and Physiology (Secondary)
Office Phone: 202-741-2710
- BA, Case Western Reserve University, 1981
- MD, Case Western Reserve University, 1985
Dr. Kaminski is an internationally recognized expert in the care of patients with myasthenia gravis. He is part of the executive committee of the NIH-funded MGTX study which is designed to evaluate the efficacy of thymectomy for myasthenia gravis. His laboratory demonstrated efficacy of complement inhibitors for myasthenia gravis in preclinical trials and now works to develop second generation complement inhibitors. Along with collaborators at GWU and across the nation, he is working to identify biomarkers that may guide future clinical trials in myasthenia gravis. He continues to study the basic biology of extraocular muscle, which he has done for 20 years.
Diplomate, American Board of Psychiatry & Neurology (Neurology) Member, American Neurological Association (elected to membership) American Academy of Neurology Association of University Professors of Neurology (President 2012-14) Association of Experimental NeuroTherapeutics Myasthenia Gravis Foundation of America (past Chair Medical Scientific Advisory Board).
View publications by this faculty member from January 1, 2013 - present
Xie Y, Li H-F, Jiang B, Li Y, Kaminski HJ, Kusner LL. Plasma IL-17 levels stratify across myasthenia gravis patient subtypes. Cytokines (in press).
Burns TM, Sanders DB, Kaminski HJ, Wolfe GI, Narayanswami P. Two steps forward one step back; Mycophenolate mofetil use for myasthenia gravis in the United States. Muscle Nerve 2015;51: 635-37.
Renton AE, Pliner HA, Provenzano C, Evoli A…Kaminski HJ…Drachman DB, Traynor BJ. A genome wide association study of myasthenia gravis. JAMA Neurol 2015;72:396-404.
Punga AR, Kaminski HJ, Richman DP, Benatar M. How clinical trials of myasthenia gravis can inform preclinical drug development. Exp Neurology 2015;270:78-81.
Kusner LL, Kaminski HJ. Special issue on standardization of preclinical evaluation of animal models for myasthenia gravis. Exp Neurology 2015;270:1-2.
Kusner LL, Marx A, Kaminski HJ, Fenstermaker RA, Ciesielski MJ. Survivin as a therapeutic target for antibody-mediated autoimmunity. PLOS ONE 2014;9:e102231.
Li Y, Tu Z, Quin S, Fung J, Kusner L, Kaminski HJ, Lu L, Lin F. Myeloid derived suppressor cells as therapy for experimental myasthenia gravis J Immunol 2014;193:2127-34.
Sengupta M, Cheema A, Kaminski HJ, Kusner LL. Metabolomic response to corticosteroid treatment among patients with myasthenia gravis. PLOS ONE 2014;9:e102635
Kaminski HJ, Busis N. The third leg of neurology training: The business of medicine. Neurology 2014;83:1778-79.
Additional publications published before January 1, 2013 may be available within Himmelfarb Library's database.
Industry Relationships and Collaborations
This faculty member (or a member of their immediate family) has reported a financial interest with the health care related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.
- ARC Biotechnology
- BT Biopharm